NVAX (Novavax) Additional Paid-In Capital : $4,513 Mil(As of Mar. 2025)

View and export this data going back to 1995. Start your Free Trial

What is Novavax Additional Paid-In Capital?

Novavax's quarterly additional paid-in capital increased from Sep. 2024 ($4,491 Mil) to Dec. 2024 ($4,501 Mil) and increased from Dec. 2024 ($4,501 Mil) to Mar. 2025 ($4,513 Mil).

Novavax's annual additional paid-in capital increased from Dec. 2022 ($3,738 Mil) to Dec. 2023 ($4,192 Mil) and increased from Dec. 2023 ($4,192 Mil) to Dec. 2024 ($4,501 Mil).

Novavax Additional Paid-In Capital Historical Data

The historical data trend for Novavax's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novavax Additional Paid-In Capital Chart

Novavax Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

Get a 7-Day Free Trial

2,535.48

3,351.97

3,737.98

4,192.16

4,501.40

Novavax Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Additional Paid-In Capital	Get a 7-Day Free Trial															4,204.78	4,477.75	4,490.63	4,501.40	4,512.85

Novavax Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Novavax Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Novavax's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Novavax Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (NAS:NVAX) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

NVAX:Mexico NVV1:Germany NVV1:Germany NVV1:Germany NVV1:Bulgaria NVAX:Austria

Address

700 Quince Orchard Road, Gaithersburg, MD, USA, 20878

Website

https://www.novavax.com

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

Executives

James F Young	director	ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Rachel K. King	director	C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Filip Dubovsky	officer: President, R&D	C/O NOVAVAX INC., 21 FIRSTFIELD ROAD, GAITHERSBURG MD 20878
Gregory M Glenn	officer: President, R&D	20 FIRSTFIELD ROAD, #250, GAITHERSBURG MD 20878
Elaine O'hara	officer: EVP, Chief Strategy Officer	333 NORTH WARREN AVENUE, MALVERN PA 19355
John C Jacobs	director, officer: President and CEO	630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Richard J Rodgers	director	C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
Herrmann John A Iii	officer: SVP, General Counsel	C/O NOVAVAX, INC., 20 FIRSTFIELD ROAD, GAITHERSBURG MD 20878
Stanley C Erck	director, officer: President and CEO	20 FIRSTFIELD ROAD, #250, GAITHERSBURG MD 20878
John Trizzino	officer: SVP, CBO and CFO	9920 BELWARD CAMPUS DRIVE, ROCKVILLE MD 20850
David M Mott	director	1119 ST. PAUL STREET, BALTIMORE MD 21202
James Patrick Kelly	officer: EVP, CFO and Treasurer	C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Gary C Evans	director	1048 TEXAN TRAIL, GRAPEVINE TX 76051
Mcmanus Michael A Jr	director	241-02 NORTHERN BLVD, DOUGLASTON NY 11362
Margaret G Mcglynn	director	C/O MERCK & CO INC, ONE MERCK DRIVE PO BOX 100, WHITEHOUSE STATION NJ 08889-0100